Sihuan Pharmaceutical Holdings Group (HKSE:00460) Interest Expense : HK$-295 Mil (TTM As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sihuan Pharmaceutical Holdings Group's interest expense for the six months ended in Dec. 2023 was HK$ -149 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-295 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sihuan Pharmaceutical Holdings Group's Operating Income for the six months ended in Dec. 2023 was HK$ -258 Mil. Sihuan Pharmaceutical Holdings Group's Interest Expense for the six months ended in Dec. 2023 was HK$ -149 Mil. Sihuan Pharmaceutical Holdings Group did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sihuan Pharmaceutical Holdings Group Interest Expense Historical Data

The historical data trend for Sihuan Pharmaceutical Holdings Group's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sihuan Pharmaceutical Holdings Group Interest Expense Chart

Sihuan Pharmaceutical Holdings Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-5.25

-9.74

-143.69

-235.82

-294.60

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial															-124.37	-116.52	-124.82	-146.07	-148.53

Sihuan Pharmaceutical Holdings Group Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-295 Mil.

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sihuan Pharmaceutical Holdings Group's Interest Expense for the six months ended in Dec. 2023 was HK$-149 Mil. Its Operating Income for the six months ended in Dec. 2023 was HK$-258 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was HK$1,047 Mil.

Sihuan Pharmaceutical Holdings Group's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Sihuan Pharmaceutical Holdings Group did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (HKSE:00460) » Definitions » Interest Expense

Traded in Other Exchanges

SHPHF:USA

Address

Zhubang 2000 Business Centre, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025

Website

https://www.sihuanpharm.com

Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Digestive System, Anti-Infective, metabolism, Respiratory, Neurology, and Others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others to provide non- or minimally invasive medical aesthetics comprehensive solutions; the innovative medicine and other medicine segments; and the generic medicine segment.

Executives

Che Fengsheng	2201 Interest of corporation controlled by you
Guo Weicheng	2201 Interest of corporation controlled by you
Meng Xianhui	2201 Interest of corporation controlled by you
Zhang Jionglong	2201 Interest of corporation controlled by you
Mingyao Capital Limited	2401 A concert party to an agreement to buy shares
Network Victory Limited	2401 A concert party to an agreement to buy shares
Proper Process International Limited	2401 A concert party to an agreement to buy shares
Successmax Global Holdings Limited	2101 Beneficial owner
Victory Faith International Limited	2401 A concert party to an agreement to buy shares
Ubs Tc (jersey) Ltd	2301 Trustee
Ubs Trustees (cayman) Ltd.	2301 Trustee
Smart Top Overseas Limited	2501 Other
Plenty Gold Enterprises Limited	2307 Founder of a discretionary trust who can infl

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Headlines

No Headlines